Differing SARs and MOAs emerge for the highly potent anti-VZV, BCNAs, and their anti-HCMV dd analogues

Christopher McGuigan; O Bidet; Antonella Carangio; G Luoni; Graciela Andreï; Robert Snoeck; De Clercq Erik; Jan Balzarini

Related publications

Article2006

Pre-clinical development of the BCNAs: The most potent anti-VZV agents reported to date

Christopher McGuigan, Ranjith Pathirana, Marco Migliore, Rina Adak, Annette Angell, G Henson, Robert Snoeck, Graciela Andreï, De Clercq Erik, Jan Balzarini

Article2004

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella—Zoster Virus (VZV)

Rebecca Sienaert, Lieve Naesens, Andrea Brancale, Antonella Carangio, Graciela Andreï, Robert Snoeck, André B. P. Kuilenburg, De Clercq Erik, Christopher McGuigan, Jan Balzarini

Article2003

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella-Zoster Virus (VZV)

Rebecca Sienaert, Lieve Naesens, Andrea Brancale, Antonella Carangio, Graciela Andreï, Robert Snoeck, André B. P. Kuilenburg, De Clercq Erik, Christopher McGuigan, Jan Balzarini

Article2003

Novel bicyclic furanopyrimidines with dual anti-VZV and -HCMV activity

Christopher McGuigan, Andrea Brancale, Graciela Andreï, Robert Snoeck, De Clercq Erik, Jan Balzarini